Dishman Pharma’s arm completes US FDA PAI for a new hi potency drug

Dishman Pharmaceuticals and Chemicals’ Switzerland based wholly owned subsidiary -- Carbogen Amcis AG -- has successfully completed US Food and Drug Administration (US FDA)  Pre Approval Inspection (PAI) for a new hi potency drug for a US multinational.

Carbogen Amcis is a leading service provider, offering a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industry, at all stages of drug development.

Dishman Pharmaceuticals and Chemicals (DPCL) is engaged in manufacturing of Bulk API, Intermediates, Specialties and Quats. The company has started production of a range of phase transfer catalysts and quaternary ammonium and phosphonium compounds in 1989.